180 Attwell Drive, Suite 360
Toronto, ON, Canada
M9W 6A9
Tel: (416) 675-8280
Fax: (416) 675-8301
Email: ir@cangene.com
| Symbol | Value | Date | Time | Change | Volume |
| CNJ.TO | 3.55 | 7/30/2010 | 10:14am | -0.05 | 6300 |
Corporate Profile
Cangene is a profitable and fully integrated developer and manufacturer of immune therapeutics, primarily targeting exigent infectious disease and biodefense applications. We have five products that have been approved in the United States and/or Canada and, with three products included in the U.S. Strategic National Stockpile, we are one of the largest civilian suppliers to the U.S. government. We began delivering on two U.S. government contracts during fiscal 2008, recording $76 million in related revenues during the year, and this was only a small portion of the total US$505-million combined value of the contracts.
With nearly 30 years of experience making our lead drug, WinRho® SDF, manufacturing capability is one of Cangene's key strengths. Along with producing our own drugs, we operate a successful contract R&D and manufacturing business using our Health Canada and FDA-inspected facilities.
Most of Cangene's products are hyperimmunes—purified antibody products that are specific for targets such as hepatitis B, botulism, and anthrax. In addition, we are developing monoclonal antibody technology and an innovative peptide therapeutic that may be effective in combating certain antibiotic-resistant infections. Rounding out our product portfolio are two recombinant protein therapeutics, made in one of our specialized manufacturing facilities.
Cangene has been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ. The Company has operations in Manitoba and Ontario in Canada, and California, Maryland and Florida in the United States. The majority of our 700 employees work in Winnipeg or at Cangene bioPharma, Inc., our subsidiary in Baltimore. Additional company information can be found at www.cangene.com and www.cangenebiopharma.com.This link will send you outside of the Cangene website.